Pharmaceutical giant AstraZeneca is partnering Queensland University’s technology transfer office UniQuest on a new open innovation programme that seeks to develop academic drug discovery.
Under the terms of the agreement, Queensland researchers will get access to AstraZeneca’s compounds with the view to developing novel therapies for conditions with high unmet medical need. Proposals then submitted by Queensland researchers will be jointly funded by AstraZeneca and UniQuest as they develop further.
Dean Moss, CEO of UniQuest, said: “The collaboration will help…
